FDA clearances, funding signals, and clinical trial data — decoded weekly for founders, VCs, and hospital innovators.
"Like stepping into a warmly lit apothecary where every jar is labeled in beautiful handwriting but contains something potent and precisely measured."
Real data. Real insights. Every card below is a real issue — click to preview.
Three payers moved to cover AI-assisted tumor profiling within 60 days of the Tempus round closing — a pattern that mirrors the 2021 cardiac AI wave. The next 90 days will determine if this becomes policy or noise.
Eleven of the 23 are radiology-adjacent, but the quieter story is four wound-care devices that cleared via De Novo — signaling a new FDA appetite for dermatology AI outside the hospital setting.
The 8-country trial is the largest prospective validation of any ophthalmic AI to date. Critically, sensitivity held above 93% even on commodity smartphone cameras — the hardware barrier just dropped.
The DTC clearances are narrow (AFib detection only) but the precedent is significant. Expect insurers to begin covering remote cardiac monitoring for non-diagnosed populations within 18 months.
The model uses social determinants of health data alongside clinical vitals — a combination regulators have historically flagged for bias. The IRB methodology here is worth studying before you pitch similar tools.
Mental health's share of healthtech VC has doubled since 2023, driven by employer-mandate tailwinds and the first wave of parity law enforcement actions. The category is crowded but the acquirers are circling.
Depth compounds over time. These analytical pieces from earlier issues are still shaping decisions today.
The reimbursement rate for RPM setup codes increased 22% while continuous monitoring codes were consolidated — a net positive for platforms with recurring revenue models but a cliff edge for one-time hardware plays.
Epic's API strategy made this possible. The implication for vendors: your moat is no longer the model — it's the workflow integration, the regulatory clearance, and the liability coverage.
Two are small molecule oncology compounds, one is a protein therapeutic for rare disease, and one is a repurposed generic. The repurposed compound has the most interesting IP structure — worth a deeper look before the data readout.
Seed-stage activity has collapsed while growth-stage rounds are larger than ever. The implication: the next generation of healthtech winners may already be funded, and the window for new entrants is narrowing in most categories.